Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer.
暂无分享,去创建一个
[1] D A Berry,et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.
[2] D. Tu,et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Silber,et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Smink,et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Wingo,et al. Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.
[6] R. Collins,et al. Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.
[7] B. F. Cole,et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival , 1996, The Lancet.
[8] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[9] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[10] R. Gelber,et al. Understanding adjuvant chemotherapy for breast cancer. , 1994, New England Journal of Medicine.
[11] Jack Cuzick,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .
[12] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.